Kairos Pharma Ltd. (NYSE American: KAPA) announced that CEO and Chairman Dr. John Yu will present at the 16th Annual LD Micro Invitational on May 18, 2026, at 1:00 p.m. PDT at the Luxe Sunset Boulevard Hotel in Los Angeles. During the presentation, Dr. Yu will provide an update on the company’s clinical program and partnering activities.
This presentation is significant as it offers investors and industry stakeholders insight into the progress of Kairos Pharma’s lead candidate, ENV-105, an antibody targeting CD105—a protein identified as a key driver of drug resistance and disease relapse in response to standard therapy. ENV-105 aims to reverse drug resistance and restore the effectiveness of standard therapies across multiple cancer types. Currently, ENV-105 is in a Phase 2 clinical trial for castrate-resistant prostate cancer and a Phase 1 trial for non-small cell lung cancer, addressing significant unmet medical needs.
The LD Micro Invitational is a key event for emerging growth companies, providing a platform for management to present their strategies and milestones to a broad audience of investors. Kairos Pharma’s participation underscores its commitment to advancing its oncology pipeline and seeking partnerships to accelerate development.
Kairos Pharma, based in Los Angeles, California, is at the forefront of oncology therapeutics, utilizing structural biology to overcome drug resistance and immune suppression in cancer. The company’s lead candidate, ENV-105, has not yet been approved as safe or effective by the United States Food and Drug Administration or any other comparable foreign regulator.
For more information on the latest news and updates relating to KAPA, visit the company’s newsroom at https://ibn.fm/KAPA. The full press release is available at https://ibn.fm/g3aQY.
